New phase 1 SURPASS trial cohort: Early-line ADP-A2M4CD8 T-cell receptor T-cell therapy plus pembrolizumab in urothelial carcinoma. Journal of Clinical Oncology February 2024;42:TPS708-TPS708
Date
02/01/2024DOI
10.1200/JCO.2024.42.4_suppl.TPS708Scopus ID
2-s2.0-105024695982 (requires institutional sign-in at Scopus site) 5 CitationsAuthor List
Aggen DH, Garcia A, Saro Suarez JM, Sauer A, Cristiani S, Brophy FE, Streets S, Norry E, Nelson AA, Kilari D, Garmezy B, Charlson JA, Zugazagoitia J, Calvo E, Moreno I, Moreno V, Hoimes CJ, Hong DS, Cervantes AAuthors
John A. Charlson MD Associate Professor in the Medicine department at Medical College of WisconsinDeepak Kilari MD Associate Professor in the Medicine department at Medical College of Wisconsin









